{"id":7655,"date":"2016-02-12T20:51:45","date_gmt":"2016-02-12T20:51:45","guid":{"rendered":"https:\/\/www.neuro-outaouais.com\/?p=2137"},"modified":"2016-02-12T20:51:45","modified_gmt":"2016-02-12T20:51:45","slug":"ocrelizumab","status":"publish","type":"post","link":"https:\/\/www.neuro-outaouais.com\/fr\/ocrelizumab\/","title":{"rendered":"Ocrelizumab : Le nouvel espoir dans le traitement de la scl\u00e9rose en plaques (SEP)"},"content":{"rendered":"

\t\t\t\tL\u2019Ocrelizumab, s\u2019agit non seulement d\u2019un traitement efficace pour la SEP r\u00e9currente, il est le premier m\u00e9dicament exp\u00e9rimental \u00e0 d\u00e9montrer un b\u00e9n\u00e9fice significatif chez les personnes atteintes de SEP primaire progressif.<\/p>\n

Jusqu\u2019\u00e0 pr\u00e9sent, la SEP primaire progressif a \u00e9t\u00e9 consid\u00e9r\u00e9 une maladie sans traitement efficace; une situation d\u00e9courageante pour les personnes atteintes, et frustrante pour les professionnels m\u00e9dicaux d\u00e9vou\u00e9s \u00e0 les aider.<\/p>\n

Pour les participants atteints de la SEP r\u00e9currente, les \u00e9tudes OPERA et OPERA II ont d\u00e9montr\u00e9 que l’Ocrelizumab r\u00e9duit le taux annuel de r\u00e9cidives de pr\u00e8s de moiti\u00e9, par rapport \u00e0 l’interf\u00e9ron b\u00eata-1a. Elles ont aussi d\u00e9montr\u00e9 une r\u00e9duction d\u2019environ 40\u00a0% de la progression confirm\u00e9e de l\u2019invalidit\u00e9 sur 12 et 24 semaines, et une r\u00e9duction significative d\u2019inflammation dans le nombre de l\u00e9sions c\u00e9r\u00e9brales.<\/p>\n

L’\u00e9tude ORATORIO a pour sa part d\u00e9montr\u00e9 que, dans le cas de personnes atteinte SEP primaire progressif, l\u2019Ocrelizumab r\u00e9duit du quart le risque de progression confirm\u00e9e de l\u2019invalidit\u00e9 pendant au moins 24 semaines par rapport au placebo. Les l\u00e9sions c\u00e9r\u00e9brales ont l\u00e9g\u00e8rement diminu\u00e9 avec l’Ocrelizumab, alors qu\u2019ils ont augment\u00e9 avec le placebo. De plus, le m\u00e9dicament a r\u00e9duit la perte de volume c\u00e9r\u00e9brale de 17,5 % par rapport au placebo.<\/p>\n

Il est possible que l\u2019Ocrelizumab soit bient\u00f4t accessible \u00e0 toute personne souffrant de SEP. Les r\u00e9sultats des \u00e9tudes sur l\u2019Ocrelizumab seront soumis aux autorit\u00e9s r\u00e9glementaires internationales au d\u00e9but de 2016.\t\t<\/p>\n","protected":false},"excerpt":{"rendered":"

L\u2019Ocrelizumab, s\u2019agit non seulement d\u2019un traitement efficace pour la SEP r\u00e9currente, il est le premier m\u00e9dicament exp\u00e9rimental \u00e0 d\u00e9montrer un b\u00e9n\u00e9fice significatif chez les personnes atteintes de SEP primaire progressif. Jusqu\u2019\u00e0 pr\u00e9sent, la SEP primaire progressif a \u00e9t\u00e9 consid\u00e9r\u00e9 une maladie sans traitement efficace; une situation d\u00e9courageante pour les personnes atteintes, et frustrante pour les […]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[34],"tags":[],"class_list":["post-7655","post","type-post","status-publish","format-standard","hentry","category-uncategorized-fr"],"yoast_head":"\nOcrelizumab - nouveau m\u00e9dicament pour la SEP<\/title>\n<meta name=\"description\" content=\"Ocrelizumab - le premier m\u00e9dicament efficace pour le traitement de la SEP primaire progressif\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.neuro-outaouais.com\/fr\/ocrelizumab\/\" \/>\n<meta property=\"og:locale\" content=\"fr_CA\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ocrelizumab - nouveau m\u00e9dicament pour la SEP\" \/>\n<meta property=\"og:description\" content=\"Ocrelizumab - le premier m\u00e9dicament efficace pour le traitement de la SEP primaire progressif\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.neuro-outaouais.com\/fr\/ocrelizumab\/\" \/>\n<meta property=\"og:site_name\" content=\"Neuro-Outaouais\" \/>\n<meta property=\"article:published_time\" content=\"2016-02-12T20:51:45+00:00\" \/>\n<meta name=\"author\" content=\"admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Estimation du temps de lecture\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.neuro-outaouais.com\/fr\/ocrelizumab\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.neuro-outaouais.com\/fr\/ocrelizumab\/\"},\"author\":{\"name\":\"admin\",\"@id\":\"https:\/\/www.neuro-outaouais.com\/#\/schema\/person\/e652e2647e959a2b0a7a9e08f3cd411b\"},\"headline\":\"Ocrelizumab : Le nouvel espoir dans le traitement de la scl\u00e9rose en plaques (SEP)\",\"datePublished\":\"2016-02-12T20:51:45+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.neuro-outaouais.com\/fr\/ocrelizumab\/\"},\"wordCount\":286,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/www.neuro-outaouais.com\/#organization\"},\"inLanguage\":\"fr-CA\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/www.neuro-outaouais.com\/fr\/ocrelizumab\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.neuro-outaouais.com\/fr\/ocrelizumab\/\",\"url\":\"https:\/\/www.neuro-outaouais.com\/fr\/ocrelizumab\/\",\"name\":\"Ocrelizumab - nouveau m\u00e9dicament pour la SEP\",\"isPartOf\":{\"@id\":\"https:\/\/www.neuro-outaouais.com\/#website\"},\"datePublished\":\"2016-02-12T20:51:45+00:00\",\"description\":\"Ocrelizumab - le premier m\u00e9dicament efficace pour le traitement de la SEP primaire progressif\",\"breadcrumb\":{\"@id\":\"https:\/\/www.neuro-outaouais.com\/fr\/ocrelizumab\/#breadcrumb\"},\"inLanguage\":\"fr-CA\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.neuro-outaouais.com\/fr\/ocrelizumab\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.neuro-outaouais.com\/fr\/ocrelizumab\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.neuro-outaouais.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ocrelizumab : Le nouvel espoir dans le traitement de la scl\u00e9rose en plaques (SEP)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.neuro-outaouais.com\/#website\",\"url\":\"https:\/\/www.neuro-outaouais.com\/\",\"name\":\"My blog\",\"description\":\"We are a non-profit dedicated to expanding the breadth of medical care for people with neurological diseases.\",\"publisher\":{\"@id\":\"https:\/\/www.neuro-outaouais.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.neuro-outaouais.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-CA\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.neuro-outaouais.com\/#organization\",\"name\":\"My blog\",\"url\":\"https:\/\/www.neuro-outaouais.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-CA\",\"@id\":\"https:\/\/www.neuro-outaouais.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.neuro-outaouais.com\/wp-content\/uploads\/2025\/04\/21f72584-071b-4bae-ab40-e19dc1dfa7ff.png\",\"contentUrl\":\"https:\/\/www.neuro-outaouais.com\/wp-content\/uploads\/2025\/04\/21f72584-071b-4bae-ab40-e19dc1dfa7ff.png\",\"width\":180,\"height\":89,\"caption\":\"My blog\"},\"image\":{\"@id\":\"https:\/\/www.neuro-outaouais.com\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.neuro-outaouais.com\/#\/schema\/person\/e652e2647e959a2b0a7a9e08f3cd411b\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-CA\",\"@id\":\"https:\/\/www.neuro-outaouais.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/dbee712dc7cef21f419072c5542df6d4a743d6bb02df10975d34622ed3a9f2c2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/dbee712dc7cef21f419072c5542df6d4a743d6bb02df10975d34622ed3a9f2c2?s=96&d=mm&r=g\",\"caption\":\"admin\"},\"sameAs\":[\"https:\/\/www.neuro-outaouais.com\"],\"url\":\"https:\/\/www.neuro-outaouais.com\/fr\/author\/admin\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Ocrelizumab - nouveau m\u00e9dicament pour la SEP","description":"Ocrelizumab - le premier m\u00e9dicament efficace pour le traitement de la SEP primaire progressif","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.neuro-outaouais.com\/fr\/ocrelizumab\/","og_locale":"fr_CA","og_type":"article","og_title":"Ocrelizumab - nouveau m\u00e9dicament pour la SEP","og_description":"Ocrelizumab - le premier m\u00e9dicament efficace pour le traitement de la SEP primaire progressif","og_url":"https:\/\/www.neuro-outaouais.com\/fr\/ocrelizumab\/","og_site_name":"Neuro-Outaouais","article_published_time":"2016-02-12T20:51:45+00:00","author":"admin","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"admin","Estimation du temps de lecture":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.neuro-outaouais.com\/fr\/ocrelizumab\/#article","isPartOf":{"@id":"https:\/\/www.neuro-outaouais.com\/fr\/ocrelizumab\/"},"author":{"name":"admin","@id":"https:\/\/www.neuro-outaouais.com\/#\/schema\/person\/e652e2647e959a2b0a7a9e08f3cd411b"},"headline":"Ocrelizumab : Le nouvel espoir dans le traitement de la scl\u00e9rose en plaques (SEP)","datePublished":"2016-02-12T20:51:45+00:00","mainEntityOfPage":{"@id":"https:\/\/www.neuro-outaouais.com\/fr\/ocrelizumab\/"},"wordCount":286,"commentCount":0,"publisher":{"@id":"https:\/\/www.neuro-outaouais.com\/#organization"},"inLanguage":"fr-CA","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.neuro-outaouais.com\/fr\/ocrelizumab\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.neuro-outaouais.com\/fr\/ocrelizumab\/","url":"https:\/\/www.neuro-outaouais.com\/fr\/ocrelizumab\/","name":"Ocrelizumab - nouveau m\u00e9dicament pour la SEP","isPartOf":{"@id":"https:\/\/www.neuro-outaouais.com\/#website"},"datePublished":"2016-02-12T20:51:45+00:00","description":"Ocrelizumab - le premier m\u00e9dicament efficace pour le traitement de la SEP primaire progressif","breadcrumb":{"@id":"https:\/\/www.neuro-outaouais.com\/fr\/ocrelizumab\/#breadcrumb"},"inLanguage":"fr-CA","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.neuro-outaouais.com\/fr\/ocrelizumab\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.neuro-outaouais.com\/fr\/ocrelizumab\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.neuro-outaouais.com\/"},{"@type":"ListItem","position":2,"name":"Ocrelizumab : Le nouvel espoir dans le traitement de la scl\u00e9rose en plaques (SEP)"}]},{"@type":"WebSite","@id":"https:\/\/www.neuro-outaouais.com\/#website","url":"https:\/\/www.neuro-outaouais.com\/","name":"My blog","description":"We are a non-profit dedicated to expanding the breadth of medical care for people with neurological diseases.","publisher":{"@id":"https:\/\/www.neuro-outaouais.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.neuro-outaouais.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-CA"},{"@type":"Organization","@id":"https:\/\/www.neuro-outaouais.com\/#organization","name":"My blog","url":"https:\/\/www.neuro-outaouais.com\/","logo":{"@type":"ImageObject","inLanguage":"fr-CA","@id":"https:\/\/www.neuro-outaouais.com\/#\/schema\/logo\/image\/","url":"https:\/\/www.neuro-outaouais.com\/wp-content\/uploads\/2025\/04\/21f72584-071b-4bae-ab40-e19dc1dfa7ff.png","contentUrl":"https:\/\/www.neuro-outaouais.com\/wp-content\/uploads\/2025\/04\/21f72584-071b-4bae-ab40-e19dc1dfa7ff.png","width":180,"height":89,"caption":"My blog"},"image":{"@id":"https:\/\/www.neuro-outaouais.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.neuro-outaouais.com\/#\/schema\/person\/e652e2647e959a2b0a7a9e08f3cd411b","name":"admin","image":{"@type":"ImageObject","inLanguage":"fr-CA","@id":"https:\/\/www.neuro-outaouais.com\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/dbee712dc7cef21f419072c5542df6d4a743d6bb02df10975d34622ed3a9f2c2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/dbee712dc7cef21f419072c5542df6d4a743d6bb02df10975d34622ed3a9f2c2?s=96&d=mm&r=g","caption":"admin"},"sameAs":["https:\/\/www.neuro-outaouais.com"],"url":"https:\/\/www.neuro-outaouais.com\/fr\/author\/admin\/"}]}},"_links":{"self":[{"href":"https:\/\/www.neuro-outaouais.com\/fr\/wp-json\/wp\/v2\/posts\/7655","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.neuro-outaouais.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.neuro-outaouais.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.neuro-outaouais.com\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.neuro-outaouais.com\/fr\/wp-json\/wp\/v2\/comments?post=7655"}],"version-history":[{"count":0,"href":"https:\/\/www.neuro-outaouais.com\/fr\/wp-json\/wp\/v2\/posts\/7655\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.neuro-outaouais.com\/fr\/wp-json\/wp\/v2\/media?parent=7655"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.neuro-outaouais.com\/fr\/wp-json\/wp\/v2\/categories?post=7655"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.neuro-outaouais.com\/fr\/wp-json\/wp\/v2\/tags?post=7655"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}